Page last updated: 2024-12-07

n-acetyldopamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetyldopamine (NADA) is a naturally occurring catecholamine, a derivative of dopamine, found in the mammalian brain and other tissues. It is synthesized through the enzymatic acetylation of dopamine by the enzyme N-acetyltransferase. NADA is implicated in various biological processes, including neurotransmission, inflammation, and oxidative stress. It has been shown to exert neuroprotective effects in experimental models of Parkinson's disease, potentially by reducing oxidative stress and inflammation. Its role in neurotransmitter signaling and its potential therapeutic applications are actively being investigated.'

N-acetyldopamine : A secondary carboxamide obtained by formal condensation of the carboxy group of acetic acid with the amino group of dopamine. A dopamine metabolite. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID100526
CHEMBL ID137743
CHEBI ID125678
SCHEMBL ID328568
MeSH IDM0048885

Synonyms (49)

Synonym
bdbm50035608
n-acetyldopamine
acetamide, n-(3,4-dihydroxyphenethyl)-
acetamide, n-(2-(3,4-dihydroxyphenyl)ethyl)-
brn 2806306
nsc 314644
nsc-314644
2494-12-4
nsc314644
acetamide,4-dihydroxyphenethyl)-
acetamide,4-dihydroxyphenyl)ethyl]-
EU-0100093
NCGC00015101-01
lopac-a-8762
LOPAC0_000093
NCGC00093595-01
NCGC00093595-02
n-acetyldopamine monohydrate
NCGC00015101-02
n-[2-(3,4-dihydroxyphenyl)ethyl]acetamide
n-acetyl-dopamine
CHEBI:125678
A 8762
CHEMBL137743 ,
AKOS003589558
CCG-204188
NCGC00015101-03
BRD-K95847244-001-01-9
SCHEMBL328568
acetamide, n-[2-(3,4-dihydroxyphenyl)ethyl]-
Q27216289
DTXSID70179656
n-[2-(3,4-dihydroxyphenyl)ethyl]ethanimidic acid
7dp ,
n-(2-(3,4-dihydroxyphenyl)ethyl)acetamide (acd/name 4.0)
n-(3,4-dihydroxyphenethyl)-acetamide
{n-[2-(3,} 4-dihydroxyphenyl)ethyl]-acetamide
sr-01000075692
SR-01000075692-1
n-(3,4-dihydroxyphenethyl)acetamide ,
mfcd00037174
CS-0130036
D70944
AS-56736
HY-N7493
CAA49412
EN300-1692211
Z68159731
AYU97G37EM

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" For the pharmacokinetics, NAD-A showed double peaks absorption character when administered with single compound, but with higher relative bioavailability when administered with CP extracts with the similar dosage."( UPLC-QTOF-MS/MS assisted UPLC-TQ-MS/MS strategy to comparatively investigate the rat pharmacokinetics of N-acetyldopamine oligomers derived from Cicadae Periostracum.
Guo, MF; Li, SL; Long, F; Mao, Q; Xu, JD; Zhang, HH; Zhong, P; Zhou, J; Zhou, SS; Zhu, H, 2023
)
1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
acetamidesCompounds with the general formula RNHC(=O)CH3.
catecholsAny compound containing an o-diphenol component.
N-(fatty acyl)-dopamine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency56.23410.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency9.97630.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency4.22220.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency4.22220.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency17.78280.177814.390939.8107AID2147
endonuclease IVEscherichia coliPotency25.11890.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency26.67950.100020.879379.4328AID588453
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.99530.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency1.00000.540617.639296.1227AID2364; AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency39.81070.001815.663839.8107AID894
M-phase phosphoprotein 8Homo sapiens (human)Potency100.00000.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency17.78280.00106.000935.4813AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency5.62340.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)18.90000.00021.557410.0000AID1172671
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NPYLR7BAedes aegypti (yellow fever mosquito)EC50 (µMol)0.07220.03902.289918.3000AID1259426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID40757The compound was tested for inhibition of B16-BL6 melanoma cells growing in culture with 0.25 mM DFMO.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID40758The compound was tested for inhibition of B16-BL6 melanoma cells growing in culture.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents.
AID1172671Inhibition of human recombinant COX2 pre-incubated for 15 mins before arachidonic acid addition by fluorescence micro plate reader method2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Bioactive compounds from the insect Aspongopus chinensis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (22.97)18.7374
1990's22 (29.73)18.2507
2000's11 (14.86)29.6817
2010's14 (18.92)24.3611
2020's10 (13.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.91 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index29.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]